Extraskeletal myxoid chondrosarcoma
Open Access
- 4 December 2008
- Vol. 113 (12), 3364-3371
- https://doi.org/10.1002/cncr.23978
Abstract
BACKGROUND. Extraskeletal myxoid chondrosarcoma (EMC) is a genetically distinct sarcoma with a propensity for local recurrence and metastasis despite an indolent course. To the authors' knowledge, there are limited data examining chemotherapy outcomes as a guide to therapeutic decisions for unresectable disease. METHODS. The clinical behavior and treatment responses of 87 patients with EMC who were seen at 2 institutions between 1975 and 2008 were examined. RESULTS. The median age of the patients at the time of diagnosis was 49.5 years, with a male‐to‐female ratio of 2:1. For patients presenting without metastases, 37% developed local recurrence (median time of 3.3 years) and 26% developed distal recurrence (median time of 3.2 years). Approximately 13% of patients presented with metastases. The 5‐year, 10‐year, and 15‐year overall survival rates were 82%, 65%, and 58%, respectively. Twenty‐one patients received 32 evaluable courses of chemotherapy. No significant radiologic or clinical responses were noted. The median time to disease progression while receiving chemotherapy was 5.2 months. The best physician‐assessed response to chemotherapy was stable disease for at least 6 months in 25% of patients, stable disease for <6 months in 41% of patients, and disease progression in 34% of patients. The estimated progression‐free survival rates at 3 months, 4 months, 6 months, and 9 months were 69%, 65%, 40%, and 26%, respectively. CONCLUSIONS. This retrospective review highlights the poor response rate to chemotherapy and emphasizes aggressive control of localized disease as the primary approach to management. Although there are biases inherent in retrospective analyses, these data provide a benchmark for time to disease progression for the study of new agents for the treatment of patients with this diagnosis. Cancer 2008. © 2008 American Cancer Society.Keywords
This publication has 38 references indexed in Scilit:
- Regulation of oncogenic transcription factor hTAFII68-TEC activity by human glyceraldehyde-3-phosphate dehydrogenase (GAPDH)Biochemical Journal, 2007
- The gene expression profile of extraskeletal myxoid chondrosarcomaThe Journal of Pathology, 2005
- A Novel Repressive E2F6 Complex Containing the Polycomb Group Protein, EPC1, That Interacts with EZH2 in a Proliferation-specific MannerJournal of Biological Chemistry, 2005
- Coexpression of NOR1 and SIX3 proteins in extraskeletal myxoid chondrosarcomas without detectable NR4A3 fusion genesCancer Genetics and Cytogenetics, 2004
- 5-Aryl thiazolidine-2,4-diones as selective PPARγ agonistsBioorganic & Medicinal Chemistry Letters, 2003
- Extraskeletal Myxoid ChondrosarcomaClinical Orthopaedics and Related Research, 2001
- Identification of a novel fusion gene involving hTAFII68 and CHN from a t(9;17)(q22;q11.2) translocation in an extraskeletal myxoid chondrosarcomaOncogene, 1999
- The EWS/TEC fusion protein encoded by the t(9;22) chromosomal translocation in human chondrosarcomas is a highly potent transcriptional activatorOncogene, 1999
- Translocation t(9;22)(q22;q12) is a primary cytogenetic abnormality in extraskeletal myxoid chondrosarcomaInternational Journal of Cancer, 1995
- EXTRASKELETAL MYXOID CHONDROSARCOMA: A Clinicopathologic and Electron Microscopic StudyActa Pathologica Japonica, 1981